

# Pathogen-insect interaction candidate molecules for transmission-blocking control strategies of vector borne diseases

Federico Alonso Zumaya-Estrada, MSc,<sup>(1)</sup> María Carmen Rodríguez, PhD,<sup>(1)</sup> Mario Henry Rodríguez, MD, PhD.<sup>(1)</sup>

Zumaya-Estrada FA, Rodríguez MC, Rodríguez MH. Pathogen-insect interaction candidate molecules for transmission-blocking control strategies of vector borne diseases. *Salud Publica Mex* 2018;60:77-85. <https://doi.org/10.21149/8140>

Zumaya-Estrada FA, Rodríguez MC, Rodríguez MH. Moléculas candidatas para el control de enfermedades transmitidas por vector mediante el bloqueo de interacciones patógeno-insecto. *Salud Publica Mex* 2018;60:77-85. <https://doi.org/10.21149/8140>

## Abstract

**Objective.** To analyze the current knowledge of pathogen-insect interactions amenable for the design of molecular-based control strategies of vector-borne diseases. **Materials and methods.** We examined malaria, dengue, and Chagas disease pathogens and insect molecules that participate in interactions during their vectors infection. **Results.** Pathogen molecules that participate in the insect intestine invasion and induced vector immune molecules are presented, and their inclusion in transmission blocking vaccines (TBV) and in genetically modify insect (GMI) vectors or symbiotic bacteria are discussed. **Conclusion.** Disruption of processes by blocking vector-pathogen interactions provides several candidates for molecular control strategies, but TBV and GMI efficacies are still limited and other secondary effects of GMI (improving transmission of other pathogens, affectation of other organisms) should be discarded.

Keywords: immunity; arthropods; vector control; transmission

## Resumen

**Objetivo.** Analizar el conocimiento actual de las interacciones patógeno-insecto susceptibles a incluirse en el diseño de estrategias moleculares para el control de enfermedades transmitidas por vectores. **Material y métodos.** Se examinaron los agentes causales de la malaria, el dengue y la enfermedad de Chagas, y las moléculas de insectos que participan en interacciones durante la infección de sus vectores. **Resultados.** Se presentan moléculas de patógenos que participan en la invasión del intestino del insecto y moléculas inmunes inducidas en los vectores. Se discute su inclusión en vacunas bloqueadoras de transmisión (VBT) y en la modificación genética de vectores (MGI) o de sus bacterias simbióticas. **Conclusión.** La interrupción de procesos mediante el bloqueo de las interacciones patógeno-vector proporciona varios candidatos para las estrategias de control molecular, pero la eficacia de VBT y MGI es aún limitada y los efectos secundarios de MGI (aumento de la transmisión de otros patógenos y afectación de otros organismos) deben descartarse.

Palabras clave: inmunidad; artrópodos; control vectorial; transmisión

(1) Centro de Investigación sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública. Cuernavaca, Morelos, México.

Received on: August 18, 2016 • Accepted on: February 24, 2017

Corresponding author: Dr. Mario Henry Rodríguez. Centro de Investigación sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública. Av. Universidad 655 col. Santa María Ahuacatitlán. 62100 Cuernavaca, Morelos, México.  
E-mail: mhenry@insp.mx

Vector-borne diseases (VBD) cause more than one million deaths every year and represent over 17% of all infectious diseases.<sup>1</sup> For viral infections, only symptomatic treatment is available and some drugs are effective to treat malaria, but drug resistance is increasing and no effective vaccines are available.<sup>2</sup> The traditional chemical control of insect vectors faces insecticide resistance and high adaptability of the vectors to different climatic and environmental conditions.<sup>3,4</sup> The recent worldwide dispersion of Zika<sup>5</sup> and Chikungunya<sup>6</sup> highlight the inefficiency of current control strategies. New molecular control strategies aimed at blocking pathogen transmission have been proposed, but a better understanding of pathogen-vector interactions is required.<sup>7</sup>

We conducted a search in PubMed, Science Direct, and Google Scholar databases for published studies concerning the interaction of the etiological agents of dengue, malaria, and Chagas disease with their respective insect vectors. We compiled a collection of articles from which we selected studies focused on the pathogen molecules involved in the insect invasion, their consequential immune responses, and the current knowledge of control strategies based in the pathogen transmission-blocking. We discuss here the most promising molecule candidates on the base of these interactions, using three examples of epidemiological relevance: *Plasmodium* – the causative agent of malaria – transmitted by *Anopheles* mosquitoes, *Trypanosoma cruzi* – the causative agent of Chagas disease – transmitted by reduviid bugs and Dengue virus [DENV] – the causative agent of dengue fever – transmitted by *Aedes* mosquitoes.<sup>8-10</sup>


All vector-borne pathogens ought to invade, multiply and produce infective forms that reach the organ that delivers them to the vertebrate hosts. Pathogens development is intrinsically associated with the insect vectors' need of blood for growing, molting and egg production. Pathogens ingested with a blood meal, after completion of their life cycle, are transmitted in subsequent blood meals (figure 1, table I) or in the feces.

Vectors oppose microorganism with structural barriers – such as the peritrophic matrix formed in mosquitoes' midgut<sup>11</sup> and the perimicrovillar membrane formed in triatomines after a blood meal.<sup>12</sup> Constitutive prophenol oxidase cascades (PPO) leading to melanization, and the induction of reactive oxygen species (ROS) are the next line of defense and are active in the insect midgut lumen and the hemolymph that fills the haemocoel cavity surrounding the insect organs.<sup>13</sup> Insects lack the components of adaptive immunity, but possess sophisticated innate immunity responses.<sup>13</sup> These responses are induced and active, since pathogens are detected in the midgut lumen, but exert their main ac-

tivity when pathogens reach the hemolymph.<sup>13</sup> In the haemocoel, the fat body liberates lytic anti-microbial peptides (AMPs) and specialized cells in the hemolymph (hemocytes) participate in the production of PPO and ROS, as well AMPs.<sup>13</sup> Three hemocyte types have been described in mosquitoes; plasmatocytes are involved in phagocytic removal and encapsulation of large particles whilst oxidation reactions and intermediary melanization molecules are mediated by oenocytoids.<sup>14</sup> In triatomines seven types of hemocytes have been described, but their functions are not yet fully elucidated.<sup>15</sup> Detection of invaders is mediated by pathogen pattern recognition receptors (PRRs) that bind to conserved motifs on microorganisms.<sup>13</sup> This recognition induces proteolytic cascades that activate the main signal pathways (IMD, Toll, and JAK-STAT) which culminate in the translocation of transcription activators (Relish, Dorsal, and STAT) to the nucleus and their binding to gene promoters of AMPs and other effector molecules.<sup>13</sup>

## Discussion

*Malaria parasites.* In the blood meal bolus, parasites encounter a hostile environment composed by a complex microbiota and the insect digestive enzymes.<sup>16</sup> The bacterial population increases hundreds of times and may stimulate the mosquito's immune response, which includes the production of AMP, ROS and nitric oxide (NO).<sup>16</sup> *Plasmodium* gametocytes transform to gametes and fertilization produces mobile ookinetes that interact with the insect midgut molecules, invade, and establish the infection on the midgut outer surface<sup>17</sup> (figure 1). The interacting parasite and midgut molecules are the basis for transmission blocking vaccines (TBV), which aim at inducing host antibodies against molecules critical for parasite development and vector-parasite interactions. These antibodies would be ingested with the infected blood meal and interrupt the infection of mosquitoes.<sup>18</sup> Candidate molecules include the surface gamete proteins P45/48, and P230 that participate in parasite fertilization<sup>19</sup> and the ookinete surface family of proteins P25-P28 that participate in midgut invasion.<sup>20</sup> A vaccine against Pvs25, which blocks *P. vivax*, is currently the leading molecule for a TBV. Candidate midgut molecules from *Anopheles* include carboxipeptidase (CPB), whose activity is triggered by *P. falciparum*.<sup>21</sup> Other candidates include calreticulin that binds to Pvs25,<sup>22</sup> the transmembrane protein Croquemort SCR2,<sup>23</sup> myosin,<sup>24</sup> and aminopeptidase 1 (APN1);<sup>25</sup> all these interact with surface parasite ligands. APN1 is highly immunogenic and conserved among anophelines, making it possible that vaccines prepared with this antigen may be active against all human malaria vectors. However,



A) Development of *Plasmodium*, Dengue virus and *Trypanosoma cruzi* in their insect vectors

P) *Plasmodium*: mosquitoes ingest gametocytes that transform into male and female gametes ( $P^1$ ). Gametes fuse and produce zygotes ( $P^2$ ). Zygotes develop into motile ookinetes that cross the peritrophic matrix, invade the midgut and develop into oocysts, forming thousands of sporozoites ( $P^3$ ). Sporozoites released in the hemolymph invade the salivary glands ( $P^4$ ) where they are delivered to human hosts ( $P^5$ ). D) Dengue viruses ingested by the mosquito during a blood meal ( $D^1$ ) infect the midgut, produce viral particles ( $D^2$  and  $D^3$ ), that are released in the hemolymph ( $D^4$ ), and reach the salivary glands where they will be injected to new human hosts ( $D^5$ ). C) Triatomines ingest trypomastigotes ( $C^1$ ), they differentiate into epimastigotes ( $C^2$ ), and multiply in the midgut ( $C^3$ ). After transformation into epimastigotes, they multiply and differentiate into infective trypomastigotes in the hindgut where they are excreted with the feces ( $C^4$ ).

B) Immune responses raised in vectors against *Plasmodium*, DENV and *T. cruzi*

Immune responses in mosquito and triatomine vectors include AMPs synthesized by hemocytes, the fat body, the midgut epithelium, and other tissues to combat DENV, *Plasmodium*, and *T. cruzi* infection. ROS/NOS are produced in both the mosquito midgut and salivary glands, which affect the *Plasmodium* ookinete and sporozoite invasion, respectively. These molecules are also produced in the midgut of triatomines infected with *T. cruzi*. Mosquito responses against parasites include melanization in the mosquito midgut to inhibit *Plasmodium* invasion and differentiation, and the expression of complement-like molecules TEP1 that block *Plasmodium* ookinete invasion and differentiation into oocysts. The main immune response against DENV is mediated by RNAi mechanism to inhibit replication in midgut and other mosquito's tissues

**FIGURE 1. PATHOGEN DEVELOPMENT AND INDUCED IMMUNE RESPONSES IN INSECT VECTORS**

**Table I**  
**EXAMPLES OF PATHOGENS DEVELOPMENT IN INSECT VECTORS AND INDUCED IMMUNE RESPONSES**

Insect vectors	Pathogens	Disease	Transmission	Development in the vector	Key immune response	
Mosquitoes	<i>Aedes</i> spp.	Dengue virus	Dengue fever	Injection of infectious saliva during blood feeding.	Infection by a viremic blood meal. Replication in the mosquito midgut. Migration to the salivary glands.	<ul style="list-style-type: none"> <li>• AMPs</li> <li>• Caspases</li> <li>• Lysozymes</li> <li>• RNAi</li> <li>• Toll and JAK-STAT signaling pathways</li> </ul>
		Chikungunya virus	Chikungunya			<ul style="list-style-type: none"> <li>• RNAi</li> </ul>
		Yellow fever virus	Yellow fever			<ul style="list-style-type: none"> <li>• Toll and JAK-STAT signaling pathways?</li> </ul>
<i>Anopheles</i> spp.	<i>Plasmodium</i> spp.	Malaria		Ingestion of malaria gametocytes during an infected blood meal. Gamete maturation and formation of zygotes in the midgut. Asexual reproduction of haploid cells and formation of sporozoites that migrate to the salivary glands.	<ul style="list-style-type: none"> <li>• Antimicrobial peptides</li> <li>• Melanization</li> <li>• Reactive oxygen species</li> <li>• TEPI-LRIMI-APL1C complex</li> <li>• Toll, IMD and JAK STAT signaling pathways</li> </ul>	
<i>Culex</i> spp.	<i>Wuchereria bancrofti</i> , <i>Brugia malayi</i> and <i>B. timori</i>	Lymphatic filariasis		Ingestion of microfilariae with an infected blood meal. Migration of the microfilariae to the thoracic muscles and develop into third-stage infective larvae. Larvae migration to the mosquito's proboscis.	<ul style="list-style-type: none"> <li>• Toll and IMD signaling pathways</li> <li>• Antimicrobial peptides</li> <li>• Thioester-containing proteins</li> <li>• Melanization</li> <li>• Encapsulation</li> </ul>	
		West Nile fever	West Nile fever	Infection with a viremic blood meal. Replication in the mosquito midgut. Migration to the salivary glands.	<ul style="list-style-type: none"> <li>• Antimicrobial peptides</li> <li>• Antiviral gene: <i>Vago</i></li> <li>• RNAi</li> <li>• Toll signaling pathway?</li> </ul>	
Triatomine bugs	Subfamily Triatominae	<i>Trypanosoma cruzi</i>	Chagas disease	Contact between infected vector feces and open skin wounds.	Ingestion of trypomastigotes with an infected blood meal. Differentiation of the trypomastigote to amastigote and subsequently to epimastigote in the midgut. Epimastigote multiplication and transformation into infective metacyclic trypomastigotes in the hindgut.	<ul style="list-style-type: none"> <li>• Antimicrobial peptides</li> <li>• Digestive enzymes and digestive by products</li> <li>• Lysozymes</li> <li>• Reactive oxygen species</li> <li>• Trypanosome-binding lectins</li> </ul>
Sandflies	<i>Phlebotomine</i> spp.	<i>Leishmania</i> spp.	Leishmaniasis	Inoculation during blood feeding.	Ingestion of <i>Leishmania</i> with an infected blood meal. Transformation of amastigotes to promastigotes in the gut. Promastigote multiplication and transformation to metacyclic promastigote. Migration to the pharyngeal valve.	<ul style="list-style-type: none"> <li>• Antimicrobial peptides</li> <li>• Digestive enzymes and digestive by products</li> <li>• Lectins/hemagglutinins</li> <li>• Reactive oxygen species</li> </ul>
Ticks	<i>Ixodes</i> spp.	<i>Borrelia burgdorferi</i> s. l.	Lyme disease	Inoculation during blood feeding.	Ingestion of bacteria during an infected blood meal. Increased population in the midgut. Migration to the salivary glands and other tissues.	<ul style="list-style-type: none"> <li>• Antimicrobial peptides</li> <li>• Lectins/hemagglutinins</li> </ul>
		<i>Rickettsia</i> spp.	Rickettsial diseases	Inoculation during blood feeding. Contact between infected vector feces and open skin wounds.		<ul style="list-style-type: none"> <li>• Lysozymes</li> <li>• Phagocytosis</li> <li>• Reactive oxygen species</li> </ul>
Tsetse flies	<i>Glossina</i> spp.	<i>Trypanosoma brucei</i>	African trypanosomiasis	Inoculation during blood feeding.	Ingestion of trypomastigotes with an infected blood meal. Transformation of trypomastigotes to procyclic trypomastigotes, multiply by binary fission. Procyclic trypomastigotes transform into epimastigotes and multiply in salivary gland. Differentiation of the epimastigote into infective metacyclic trypomastigotes.	<ul style="list-style-type: none"> <li>• Antimicrobial peptides</li> <li>• Parasite inhibitory peptidoglycan recognition protein LB</li> <li>• Reactive oxygen species</li> <li>• Trypanosome-binding lectins</li> </ul>
Fleas	<i>Xenopsylla cheopis</i>	<i>Yersinia pestis</i>	Plague	Contact between infected regurgitated midgut contents and open skin wounds.	Ingestion of bacteria with an infected blood meal. Bacteria colonize and multiply within the midgut and proventriculus. Occlusion of the flea proventriculus due bacteria multiplication. Reflux of infected blood from the midgut to the mouthparts.	<ul style="list-style-type: none"> <li>• Antimicrobial peptides?</li> <li>• Digestive enzymes and digestive by products</li> <li>• Lysozymes</li> </ul>

not TBV completely blocks transmission and as they do not directly protect humans, their use in public health programs is still controversial.

Evidence of the participation of the IMD pathway in the mosquito immune response to *Plasmodium* is supported by the prevention of the parasite development after silencing its negative regulator *Caspar*.<sup>26</sup> Toll mediates the production of AMPs like attacin, cecropin, gambicin, and other defensins.<sup>27</sup> Lysozymes are expressed in lower quantities than AMP, but they activate the phenol oxidase (PO) cascade and some exhibit anti-*Plasmodium* activity.<sup>28</sup> The thioester containing protein (TEP1) is part of the complement-like mosquito system and part of the main system limiting *Plasmodium* infection. The midgut lesion produced by invading ookinetes, results in nitrosilation of the midgut outer surface, attracting and inducing apoptosis of hemocytes. These release microvesicles with, yet unknown, components that promote the activation of TEP1. TEP1 bound to the parasites surface participate in the parasite lysis.<sup>29</sup> TEP1 also facilitates the elimination of many sporozoites in the hemolymph (figure 1) by granulocytes, which also participate in their melanization.<sup>30</sup>

Attempts to increase mosquito resistance to *Plasmodium* by inducing the overexpression of immune molecules have shown variable success. The induction of NF- $\kappa$ B Rel2 transcription factor (IMD pathway) in midgut and fat body of *An. stephensi* resulted in an incremented but not complete resistance to *Plasmodium* infection.<sup>31</sup> Also, transgenic mosquitoes overexpressing TEP1 had reduced parasite numbers.<sup>32</sup> A memory-like response phenomenon (reduction in the intensity of infection after a previous infection) has been described in anophelines re-exposed to *Plasmodium*.<sup>33</sup> However, although this opens the possibility for transgenic construction of resistant mosquitoes, no specific mechanisms and molecules have been identified.

Although no direct effect of induced AMP on parasites has been documented, a synthetic cecropin-like peptide (Shiva 3) proved to be toxic to the sexual forms of *P. berghei*.<sup>34</sup> Meanwhile, transgenic mosquitoes expressing scorpine, a cecropine-defensin hybrid were less susceptible to this parasite.<sup>35</sup> These studies indicate the need for improving the efficacy of the effector molecule expression; for instance, the simultaneous expression of cecropin and defensin A completely blocked infection.<sup>36</sup>

*Dengue*. From an infected blood meal, DENV invade and multiply within the mosquito midgut epithelial cells, to later disseminate to other organs, reaching the salivary glands, from where they are inoculated to new human hosts in subsequent blood meals<sup>37</sup> (figure1). The virus envelope protein E (Ep) (antigenically different

in the four DENV serotypes) interacts with several epithelium surface molecules. Three midgut molecules whose expression increases with the blood meal interact with Ep and are candidates of TBV;<sup>7</sup> C-type lectins as mosGCLTL-3, carboxipeptidase B1 (CPB1) and the putative cysteine rich venom protein (CRVP379). CRVP379 interacts with prohibitin, a putative receptor for DENV, and antibodies against CRVP379 or silencing its coding gene blocks the mosquito infection. However, anti-dengue TBV encounters the same shortcoming as those against malaria; furthermore, these vaccines ought to be effective against the four DENV serotypes.

Several molecules are candidates for genetic manipulation of *Aedes* mosquitos. Although NO expressed in the mosquito midgut could inhibit DENV replication,<sup>38</sup> this is insufficient to impede infection and no attempts for engineering mosquitos to increase its production have been made. Toll activation by DENV culminate in defensins and cecropine synthesis,<sup>39</sup> but this is insufficient to control infection. On the other hand, recombinant scorpine inhibits DENV-2 replication, thus making it a candidate for transgenic resistant mosquitoes.<sup>35</sup> The inhibition of JAK-STAT results in increased DENV replication; and genetically modified *Ae. aegypti* overexpressing *Dome* or *Hop*, upon blood feeding, activate JAK/STAT in the fat body and salivary glands inhibiting DENV infection. However, this inhibition is far from complete.<sup>40</sup>

RNA interference (RNAi) gene silencing is an important antiviral mechanism in *Ae. aegypti*.<sup>41</sup> Silencing components of the RNAi pathway increases DENV replication.<sup>42</sup> Consequently, transgenic *Ae. aegypti* expressing in the midgut and salivary glands inverted RNA coding for a region of the pre-membrane viral protein depicted lower susceptibility to DENV.<sup>43,44</sup>

*Trypanosoma cruzi*. Trypomastigotes ingested in the blood meal remain for few days in the anterior part of the insect midgut; most of them transform into epimastigotes, and move to the posterior part of the midgut. The attachment of epimastigotes to the perimicrovillar membrane (PMM) seems to be essential for parasite multiplication. Reaching the rectum, they transform into metacyclic trypomastigotes. These are discharged with the feces, usually during blood feeding.<sup>45</sup> Parasite-PMM interactions are mediated through glycoinositol phospholipid molecules on the epimastigote plasma membrane.<sup>46</sup> The surface of epimastigotes are covered by mucin-type glycol-conjugates and one of them, TcSMUG L, appears to mediate the interaction of the parasite with the intestinal epithelium, intercepting this interaction has been proposed for transmission blocking strategies,<sup>47</sup> a better understanding of the molecules and

mechanisms involved in vector-parasite interactions may provide more candidates for TBV.

The increase in bacteria population within the mid-gut after each blood meal has no effect on the parasites, but *Serratia marcescens* produces prodigiosin, a pigment with trypanolytic activity.<sup>48</sup> Within the blood meal bolus, trypomastigotes agglutinated by lectins successfully develop and are highly infective, while those not agglutinated are lysed.<sup>49</sup> The transformation of epimastigotes seems to be mediated by  $\alpha$ D-globin, present in hemoglobin. This interacts with an epimastigote surface receptor, stimulates the parasites adenylyl cyclase and initiates their transformation into metacyclic trypomastigotes,<sup>50</sup> providing an interesting transmission-blocking candidate based on halting the parasite cycle.

The information on triatomine immune defenses against *T. cruzi* is scarce; some components of Toll pathway have been identified in *R. prolixus*, but they lack canonical components of IMD and JAK-STAT.<sup>51</sup> In the intestinal track, digestive enzymes have no effect on parasite survival<sup>50</sup> and NOS expression does not

eliminate infection.<sup>52</sup> Defensins in triatomines are mostly involved in the regulation of bacterial symbionts, but it has been suggested a potential function of intestinal defensin 1 in the *T. cruzi* population control.<sup>53</sup> Combination of AMPs from other insects like apidaecin, cecropin A, magainin II, and melittin, had *in vitro* additive toxicity for *T. cruzi*.<sup>54</sup> These AMPs have been used to transform (paratransgenesis) *Rhodococcus rhodnii*, a symbiotic actinomycete in the lumen of triatomines.<sup>55</sup> Triatomines carrying the transformed bacteria more effectively controlled the parasite infection.<sup>56</sup> In this transmission blocking strategy, the parasite-toxic bacteria are transmitted to the offspring via the coprophagic behavior of the immature bug.<sup>57</sup>

*Engineering strategies for genetic transformation.* The overall objective of the molecular strategies to control VBD is to re-program vector genomes. The gene constructs generate alterations in the genome (gene additions or deletions) to affect the vector's ability to transmit pathogens.<sup>58</sup> These strategies seek the introduction of

**Table II**  
**CANDIDATE MOLECULES FOR TRANSMISSION BLOCKING VACCINES AND VECTOR GENETIC MANIPULATION**

Insect vector/pathogen	Transmission blocking vaccines			Genetic manipulation			
	Blocking antibodies	Target insect/pathogen molecules	Reference	Transgenesis	Reference	Paratransgenesis	Reference
<i>Anopheles/Plasmodium</i>	Anti-P45/48, Anti-P230	APNI/Pvs25	van Dijk and colleagues, 2001 <sup>19</sup>	NF-kB Rel2 transcription factor	Dong and colleagues, 2011 <sup>31</sup>	Shiva-3	Rodriguez and colleagues, 2007 <sup>34</sup>
	Anti-P25/P28		Tomas and colleagues, 2001 <sup>20</sup>	Thioester containing protein I (TEPI)	Volohonsky and colleagues, 2017 <sup>32</sup>	Cecropine A-defensin A	Kokoza and colleagues, 2010 <sup>36</sup>
	Anti-carboxipeptidase		Lavazec and colleagues, 2007 <sup>21</sup>	Scorpine	Carballar-Lejarazú and colleagues, 2008 <sup>35</sup>		
	Anti-croquemort (SCRBQ2)		Gonzalez-Lazaro and colleagues, 2009 <sup>23</sup>				
	Anti-myosin		Lecona-Valera and colleagues, 2016 <sup>24</sup>				
<i>Aedes/Dengue virus</i>	Anti-rich venom protein 379 (CRVP379)	mosGCLTL-3, Carboxipeptidase BI (CPBI), Putative cysteine rich venom protein 379	Armistead and colleagues, 2014 <sup>25</sup>	Dome, Hop	Jupatanakul and colleagues, 2017 <sup>40</sup>	None	
			Londono-Renteria and colleagues, 2016 <sup>7</sup>	inverted RNAi	Franz and colleagues, 2006; <sup>43</sup> Mathur and colleagues, 2010 <sup>44</sup>		
				Scorpine	Carballar-Lejarazú and colleagues, 2008 <sup>35</sup>		
<i>Triatomine/T. cruzi</i>	None	TcSMUG L	Gonzalez and colleagues, 2013 <sup>47</sup>	None	None	Apidaecin, cecropin A, magainin II, and melittin	Fieck and colleagues, 2010; <sup>54</sup>
		$\alpha$ D-globin	Garcia and colleagues, 1995 <sup>50</sup>				Hurwitz and colleagues, 2012 <sup>56</sup>

heritable modified genes into the genome of wild target vector populations. A shortcoming of these strategies is that methods which modify only one allele (one chain) of the desired gene (*e.g.* transposon-mediated transformation), would spread the desired trait only to half of the offspring, and it would eventually be eliminated in the wild population. Alternative approaches use endonuclease genes capable of copying themselves to both gene alleles, which are inherited to all offspring, thus spreading more efficiently through a wild population.<sup>58</sup> One such method uses CRISPR nuclease Cas9 to cut sequences specified by guiding RNA molecules.<sup>59</sup> Endonuclease gene drives spread through populations cutting homologous chromosomes lacking the alteration, inducing the cell to copy the endonuclease and surrounding genes into the chromosome.<sup>60</sup>

In spite of the extensive advances in identifying key candidate genes for engineering resistant insect vectors, strict methodological controls to maintain the stability of the gene construct in the insect genome and to guarantee that the gene modification will not introduce alterations to the organism as a whole (pleiotropy), or produce secondary undesirable effects on the insect fitness, reproduction or capacity to transmit other pathogens. The efficacy of these strategies to control VBD depends on not yet satisfactory gene drives capable of spreading efficiently through wild populations,<sup>61</sup> but that will not spread to non-target species. Safety considerations should guaranty that the gene product will not harm other organisms, including humans.<sup>61</sup>

## Conclusions

Approaches based in the use of antibodies or genetic manipulation against critical molecules provide several candidates for VBD control (table II). These methods are mainly focused on disrupting specific vector-pathogen interactions. Successful transgenic manipulation of mosquitoes has been achieved, but their negative relative fitness in relation to wild populations is an important limitation for their large-scale use. Despite successes of altered vectors symbionts, it remains to be seen if transformed bacteria can replace non-transformed bacteria in natural insect populations. Evidently, these novel approaches involving engineered insects and bacteria raise several ethical, legal and social implications that must be addressed before they are considered as part of integrated VBD control strategies.

*Declaration of conflict of interests.* The authors declare that they have no conflict of interests.

## References

1. World Health Organization. Vector-borne diseases. Geneva: WHO 2016. Available from: <http://www.who.int/mediacentre/factsheets/fs387/en/>
2. White N. Antimalarial drug resistance and mortality in falciparum malaria. *Trop Med Int Health* 1999;4(7):469-470. <https://doi.org/10.1046/j.1365-3156.1999.00435.x>
3. Kelly-Hope L, Ranson H, Hemingway J. Lessons from the past: managing insecticide resistance in malaria control and eradication programmes. *Lancet Infect Dis* 2008;8(6):387-389. [https://doi.org/10.1016/S1473-3099\(08\)70045-8](https://doi.org/10.1016/S1473-3099(08)70045-8)
4. Mougabure-Cueto G, Picollo MI. Insecticide resistance in vector Chagas disease: evolution, mechanisms and management. *Acta Trop* 2015;149:70-85. <https://doi.org/10.1016/j.actatropica.2015.05.014>
5. Gyawali N, Bradbury RS, Taylor-Robinson AW. The global spread of Zika virus: is public and media concern justified in regions currently unaffected? *Infect Dis Poverty* 2016;5:37. <https://doi.org/10.1186/s40249-016-0132-y>
6. Nsoesie EO, Kraemer MU, Golding N, Pigott DM, Brady OJ, Moyes CL, et al. Global distribution and environmental suitability for chikungunya virus, 1952 to 2015. *Euro Surveill* 2016;21(20):pii=30234. <https://doi.org/10.2807/1560-7917.es.2016.21.20.30234>
7. Londono-Renteria B, Troupin A, Colpitts TM. Arbovirosis and potential transmission blocking vaccines. *Parasit Vectors* 2016;9:516. <https://doi.org/10.1186/s13071-016-1802-0>
8. World Health Organization. World Malaria Report 2015. Geneva: WHO 2015 Available from: <http://www.who.int/malaria/publications/world-malaria-report-2015/report/en/>
9. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. *Nature* 2013;496(7446):504-507. <https://doi.org/10.1038/nature12060>
10. World Health Organization. Chagas disease (American trypanosomiasis). Geneva: WHO, 2016 Available from: <http://www.who.int/mediacentre/factsheets/fs340/en/>
11. Lehane MJ. Peritrophic matrix structure and function. *Annu Rev Entomol* 1997;42:525-550. <https://doi.org/10.1146/annurev.ento.42.1.525>
12. Gutierrez-Cabrera AE, Cordoba-Aguilar A, Zenteno E, Lowenberger C, Espinoza B. Origin, evolution and function of the hemipteran perimicrovillar membrane with emphasis on Reduviidae that transmit Chagas disease. *Bull Entomol Res* 2016;106(3):279-291. <https://doi.org/10.1017/S0007485315000929>
13. Lemaître B, Hoffmann J. The host defense of *Drosophila melanogaster*. *Annu Rev Immunol* 2007;25:697-743. <https://doi.org/10.1146/annurev.immunol.25.022106.141615>
14. Hernandez-Martinez S, Lanz H, Rodriguez MH, Gonzalez-Ceron L, Tsutsumi V. Cellular-mediated reactions to foreign organisms inoculated into the hemocoel of *Anopheles albimanus* (Diptera: Culicidae). *J Med Entomol* 2002;39(1):61-69. <https://doi.org/10.1603/0022-2585-39.1.61>
15. de Azambuja P, Garcia ES, Ratcliffe NA. Aspects of classification of Hemiptera hemocytes from six triatomine species. *Mem Inst Oswaldo Cruz* 1991;86(1):1-10. <https://doi.org/10.1590/S0074-02761991000100002>
16. Clayton AM, Dong Y, Dimopoulos G. The *Anopheles* innate immune system in the defense against malaria infection. *J Innate Immun* 2014;6:169-181. <https://doi.org/10.1159/000353602>
17. Sinden RE. The cell biology of malaria infection of mosquito: advances and opportunities. *Cell Microbiol* 2015;17(4):451-466. <https://doi.org/10.1111/cmi.12413>
18. Kaslow DC. Immunogenicity of *Plasmodium falciparum* sexual stage antigens: implications for the design of a transmission blocking

- vaccine. *Immunol Lett* 1990;25(1-3):83-86. [https://doi.org/10.1016/0165-2478\(90\)90096-9](https://doi.org/10.1016/0165-2478(90)90096-9)
19. van Dijk MR, Janse CJ, Thompson J, Waters AP, Braks JA, Dodemont HJ, et al. A central role for P48/45 in malaria parasite male gamete fertility. *Cell* 2001;104(1):153-164. [https://doi.org/10.1016/S0092-8674\(01\)00199-4](https://doi.org/10.1016/S0092-8674(01)00199-4)
20. Tomas AM, Margos G, Dimopoulos G, van Lin LH, de Koning-Ward TF, Sinha R, et al. P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions. *EMBO J* 2001;20(15):3975-3983. <https://doi.org/10.1093/emboj/20.15.3975>
21. Lavazec C, Boudin C, Lacroix R, Bonnet S, Diop A, Thiberge S, et al. Carboxypeptidases B of *Anopheles gambiae* as targets for a *Plasmodium falciparum* transmission-blocking vaccine. *Infect Immun* 2007;75:1635-1642. <https://doi.org/10.1128/IAI.00864-06>
22. Rodriguez M del C, Martinez-Barnetche J, Alvarado-Delgado A, Batista C, Argotte-Ramos RS, Hernandez-Martinez S, et al. The surface protein Pvs25 of *Plasmodium vivax* ookinetes interacts with calreticulin on the midgut apical surface of the malaria vector *Anopheles albimanus*. *Mol Biochem Parasitol* 2007;153(2):167-177. <https://doi.org/10.1016/j.molbiopara.2007.03.002>
23. Gonzalez-Lazaro M, Dinglasan RR, Hernandez-Hernandez F de L, Rodriguez MH, Laclaustra M, Jacobs-Lorena M, et al. Anopheles gambiae Croquemort SCR2, expression profile in the mosquito and its potential interaction with the malaria parasite *Plasmodium berghei*. *Insect Biochem Mol Biol* 2009;39(5-6):395-402. <https://doi.org/10.1016/j.ibmb.2009.03.008>
24. Lecona-Valera AN, Tao D, Rodriguez MH, Lopez T, Dinglasan RR, Rodriguez MC. An antibody against an *Anopheles albimanus* midgut myosin reduces *Plasmodium berghei* oocyst development. *Parasit Vectors* 2016;9(2):274. <https://doi.org/10.1186/s13071-016-1548-8>
25. Armistead JS, Morlais I, Mathias DK, Jardim JG, Joy J, Fridman A, et al. Antibodies to a single, conserved epitope in *Anopheles* APN1 inhibit universal transmission of *Plasmodium falciparum* and *Plasmodium vivax* malaria. *Infect Immun* 2014;82(2):818-829. <https://doi.org/10.1128/IAI.01222-13>
26. Garver LS, Dong Y, Dimopoulos G. Caspar controls resistance to *Plasmodium falciparum* in diverse anopheline species. *PLoS Pathog* 2009;5(3):e1000335. <https://doi.org/10.1371/journal.ppat.1000335>
27. Dimopoulos G, Richman A, Muller HM, Kafatos FC. Molecular immune responses of the mosquito *Anopheles gambiae* to bacteria and malaria parasites. *Proc Natl Acad Sci U S A* 1997;94(21):11508-11513. <https://doi.org/10.1073/pnas.94.21.11508>
28. Rao XJ, Ling E, Yu XQ. The role of lysozyme in the prophenoloxidase activation system of *Manduca sexta*: an in vitro approach. *Dev Comp Immunol* 2010;34(3):264-271. <https://doi.org/10.1016/j.dci.2009.10.004>
29. Castillo JC, Ferreira ABB, Trisnadi N, Barillas-Mury C. Activation of mosquito complement antiplasmodial response requires cellular immunity. *Science Immunology* 2017;2(7):eaal1505. <https://doi.org/10.1126/sciimmunol.aal1505>
30. Hillyer JF, Schmidt SL, Christensen BM. Rapid phagocytosis and melanization of bacteria and *Plasmodium* sporozoites by hemocytes of the mosquito *Aedes aegypti*. *J Parasitol* 2003;89(1):62-69. [https://doi.org/10.1645/0022-3395\(2003\)089\[0062:RPAMOB\]2.0.CO;2](https://doi.org/10.1645/0022-3395(2003)089[0062:RPAMOB]2.0.CO;2)
31. Dong Y, Das S, Cirimotich C, Souza-Neto JA, McLean KJ, Dimopoulos G. Engineered anopheles immunity to *Plasmodium* infection. *PLoS Pathog* 2011;7(12):e1002458. <https://doi.org/10.1371/journal.ppat.1002458>
32. Volohonsky G, Hopp AK, Saenger M, Soichot J, Scholze H, Boch J, et al. Transgenic Expression of the Anti-parasitic Factor TEPI in the Malaria Mosquito *Anopheles gambiae*. *PLoS Pathog* 2017;13(1):e1006113. <https://doi.org/10.1371/journal.ppat.1006113>
33. Rodrigues J, Brayner FA, Alves LC, Dixit R, Barillas-Mury C. Hemocyte differentiation mediates innate immune memory in *Anopheles gambiae* mosquitoes. *Science* 2010;329(5997):1353-1355. <https://doi.org/10.1126/science.1190689>
34. Rodriguez MC, Zamudio F, Torres JA, Gonzalez-Ceron L, Possani LD, Rodriguez MH. Effect of a cecropin-like synthetic peptide (Shiva-3) on the sporogonic development of *Plasmodium berghei*. *Exp Parasitol* 1995;80(4):596-604. <https://doi.org/10.1006/expr.1995.1075>
35. Carballar-Lejarazu R, Rodriguez MH, de la Cruz Hernandez-Hernandez F, Ramos-Castaneda J, Possani LD, Zurita-Ortega M, et al. Recombinant scorpine: a multifunctional antimicrobial peptide with activity against different pathogens. *Cell Mol Life Sci* 2008;65(19):3081-3092. <https://doi.org/10.1007/s00018-008-8250-8>
36. Kokoza V, Ahmed A, Woon Shin S, Okafor N, Zou Z, Raikhel AS. Blocking of *Plasmodium* transmission by cooperative action of Cecropin A and Defensin A in transgenic *Aedes aegypti* mosquitoes. *Proc Natl Acad Sci U S A* 2010;107(18):8111-8116. <https://doi.org/10.1073/pnas.1003056107>
37. Salazar MI, Richardson JH, Sanchez-Vargas I, Olson KE, Beaty BJ. Dengue virus type 2: replication and tropisms in orally infected *Aedes aegypti* mosquitoes. *BMC Microbiol* 2007;7:9. <https://doi.org/10.1186/1471-2180-7-9>
38. Takhampunya R, Padmanabhan R, Ubol S. Antiviral action of nitric oxide on dengue virus type 2 replication. *J Gen Virol* 2006;87:3003-3011. <https://doi.org/10.1099/vir.0.81880-0>
39. Xi Z, Ramirez JL, Dimopoulos G. The *Aedes aegypti* toll pathway controls dengue virus infection. *PLoS Pathog* 2008;4(7):e1000098. <https://doi.org/10.1371/journal.ppat.1000098>
40. Jupatanakul N, Sim S, Anglero-Rodriguez YI, Souza-Neto J, Das S, Poti KE, et al. Engineered *Aedes aegypti* JAK/STAT Pathway-Mediated Immunity to Dengue Virus. *PLoS Negl Trop Dis* 2017;11(1):e0005187. <https://doi.org/10.1371/journal.pntd.0005187>
41. Blair CD. Mosquito RNAi is the major innate immune pathway controlling arbovirus infection and transmission. *Future Microbiol* 2011;6(3):265-277. <https://doi.org/10.2217/fmb.11.11>
42. Sanchez-Vargas I, Scott JC, Poole-Smith BK, Franz AW, Barbosa-Solomieu V, Wilusz J, et al. Dengue virus type 2 infections of *Aedes aegypti* are modulated by the mosquito's RNA interference pathway. *PLoS Pathog* 2009;5(2):e1000299. <https://doi.org/10.1371/journal.ppat.1000299>
43. Franz AW, Sanchez-Vargas I, Adelman ZN, Blair CD, Beaty BJ, James AA, et al. Engineering RNA interference-based resistance to dengue virus type 2 in genetically modified *Aedes aegypti*. *Proc Natl Acad Sci U S A* 2006;103(11):4198-4203. <https://doi.org/10.1073/pnas.0600479103>
44. Mathur G, Sanchez-Vargas I, Alvarez D, Olson KE, Marinotti O, James AA. Transgene-mediated suppression of dengue viruses in the salivary glands of the yellow fever mosquito, *Aedes aegypti*. *Insect Mol Biol* 2010;19(6):753-763. <https://doi.org/10.1111/j.1365-2583.2010.01032.x>
45. Kollien AH, Schaub GA. The development of *Trypanosoma cruzi* in triatominae. *Parasitol Today* 2000;16(9):381-387. [https://doi.org/10.1016/S0169-4758\(00\)01724-5](https://doi.org/10.1016/S0169-4758(00)01724-5)
46. Garcia E, Gonzalez M, Azambuja P. Biological factors involving *Trypanosoma cruzi* life cycle in the invertebrate vector, *Rhodnius prolixus*. *Mem Inst Oswaldo Cruz* 1999;94(suppl 1):213-216. <https://doi.org/10.1590/S0074-02761999000700033>
47. Gonzalez MS, Souza MS, Garcia ES, Nogueira NF, Mello CB, Canepa GE, et al. *Trypanosoma cruzi* TcSMUG L-surface mucins promote development and infectivity in the triatomine vector *Rhodnius prolixus*. *PLoS Negl Trop Dis* 2013;7(11):e2552. <https://doi.org/10.1371/journal.pntd.0002552>
48. Azambuja P, Feder D, Garcia ES. Isolation of *Serratia marcescens* in the midgut of *Rhodnius prolixus*: impact on the establishment of the parasite *Trypanosoma cruzi* in the vector. *Exp Parasitol* 2004;107(1-2):89-96. <https://doi.org/10.1016/j.exppara.2004.04.007>
49. Mello CB, Garcia ES, Ratcliffe NA, Azambuja P. *Trypanosoma cruzi* and *Trypanosoma rangeli*: interplay with hemolymph components of *Rhodnius prolixus*. *J Invertebr Pathol* 1995;65(3):261-268. <https://doi.org/10.1006/jipa.1995.1040>
50. Garcia ES, Gonzalez MS, de Azambuja P, Baralle FE, Fraidenraich D, Torres HN, et al. Induction of *Trypanosoma cruzi* metacyclogenesis in the gut of the hematophagous insect vector, *Rhodnius prolixus*, by hemoglobin and peptides carrying alpha D-globin sequences. *Exp Parasitol* 1995;81(3):255-261. <https://doi.org/10.1006/expr.1995.1116>



51. Mesquita RD, Vionette-Amaral RJ, Lowenberger C, Rivera-Pomar R, Monteiro FA, Minx P, et al. Genome of *Rhodnius prolixus*, an insect vector of Chagas disease, reveals unique adaptations to hematophagy and parasite infection. *Proc Natl Acad Sci U S A* 2015; 112(48):14936-14941. <https://doi.org/10.1073/pnas.1506226112>
52. Whitten MM, Mello CB, Gomes SA, Nigam Y, Azambuja P, Garcia ES, et al. Role of superoxide and reactive nitrogen intermediates in *Rhodnius prolixus* (Reduviidae)/*Trypanosoma rangeli* interactions. *Exp Parasitol* 2001; 98(1):44-57. <https://doi.org/10.1006/expr.2001.4615>
53. Waniek PJ, Jansen AM, Araujo CA. *Trypanosoma cruzi* infection modulates the expression of *Triatoma brasiliensis* def1 in the midgut. *Vector Borne Zoonotic Dis* 2011; 11(7):845-847. <https://doi.org/10.1089/vbz.2010.0020>
54. Fieck A, Hurwitz I, Kang AS, Durvasula R. *Trypanosoma cruzi*: synergistic cytotoxicity of multiple amphipathic anti-microbial peptides to *T. cruzi* and potential bacterial hosts. *Exp Parasitol* 2010; 125(4):342-347. <https://doi.org/10.1016/j.exppara.2010.02.016>
55. Baines S. The role of the symbiotic bacteria in the nutrition of *Rhodnius prolixus*. *J Exp Biol* 1956; 33:533-541.
56. Hurwitz I, Fieck A, Durvasula R. Antimicrobial peptide delivery strategies: use of recombinant antimicrobial peptides in paratransgenic control systems. *Curr Drug Targets* 2012; 13(16):1173-1180. <https://doi.org/10.2174/138945012802002366>
57. Durvasula RV, Gumbs A, Panackal A, Kruglov O, Aksoy S, Merrifield RB, et al. Prevention of insect-borne disease: an approach using transgenic symbiotic bacteria. *Proc Natl Acad Sci U S A* 1997; 94(7):3274-3278. <https://doi.org/10.1073/pnas.94.7.3274>
58. Burt A. Site-specific selfish genes as tools for the control and genetic engineering of natural populations. *Proc Biol Sci* 2003; 270(1518):921-928. <https://doi.org/10.1098/rspb.2002.2319>
59. Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for engineering biology. *Nat Methods* 2013; 10:957-963. <https://doi.org/10.1038/nmeth.2649>
60. Esvelt KM, Smidler AL, Catteruccia F, Church GM. Concerning RNA-guided gene drives for the alteration of wild populations. *Elife* 2014; 3:e03401. <https://doi.org/10.7554/eLife.03401>
61. Oye KA, Esvelt K, Appleton E, Catteruccia F, Church G, Kuiken T, et al. Biotechnology. Regulating gene drives. *Science* 2014; 345(6197):626-628. <https://doi.org/10.1126/science.1254287>